AstraZeneca breathes sigh of relief as court blocks US Symbicort genericA US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing Share XAstraZeneca breathes sigh of relief as court blocks US Symbicort generichttps://pharmaphorum.com/news/astrazeneca-breathes-sigh-of-relief-as-court-blocks-us-symbicort-generic/
EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
AbbVie won’t enforce patents for COVID-19 drug candidate KaletraAbbVie has said it won’t defend patent rights to its HIV therapy Kaletra in the hope that it Share XAbbVie won’t enforce patents for COVID-19 drug candidate Kaletrahttps://pharmaphorum.com/news/abbvie-wont-enforce-patents-for-covid-19-drug-candidate-kaletra/
Biogen claims victory in patent dispute with Mylan over MS drug TecfideraShares in Biogen are on the rise after the company successfully defended its blockbuster multiple sclerosis drug Tecfidera Share XBiogen claims victory in patent dispute with Mylan over MS drug Tecfiderahttps://pharmaphorum.com/news/biogen-claims-victory-in-patent-dispute-with-mylan-over-ms-drug-tecfidera/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Indivior hit hard as generic Suboxone defence crumblesIndivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the Share XIndivior hit hard as generic Suboxone defence crumbleshttps://pharmaphorum.com/news/indivior-hit-hard-as-generic-suboxone-defence-crumbles/
